Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-607-0800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$206.63 million
Profitability
Miscellaneous
Employees113
Next Earnings Date11/21/2019 (Confirmed)
OptionableOptionable
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its earnings results on Tuesday, August, 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.98 by $0.01. The biotechnology company earned $57.26 million during the quarter, compared to the consensus estimate of $56.59 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
What price target have analysts set for ENTA?
4 equities research analysts have issued 12-month price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.00 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.
What is the consensus analysts' recommendation for Enanta Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.
Has Enanta Pharmaceuticals been receiving favorable news coverage?
Media headlines about ENTA stock have been trending positive on Thursday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Allakos (ALLK), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Alkermes (ALKS), FibroGen (FGEN), HUTCHISON CHINA/S (HCM) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Enanta Pharmaceuticals own?
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
- Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
- Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
- Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)
Who are Enanta Pharmaceuticals' major shareholders?
Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.49%), Rhumbline Advisers (0.26%), Alps Advisors Inc. (0.20%), New York State Teachers Retirement System (0.20%), California Public Employees Retirement System (0.18%) and Mackay Shields LLC (0.11%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Which major investors are selling Enanta Pharmaceuticals stock?
ENTA stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Dupont Capital Management Corp, Alps Advisors Inc., Navellier & Associates Inc, Systematic Financial Management LP, New York State Teachers Retirement System and Advantage Investment Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.
Which major investors are buying Enanta Pharmaceuticals stock?
ENTA stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, California Public Employees Retirement System, Russell Investments Group Ltd., State of Alaska Department of Revenue, Wedge Capital Management L L P NC, Mackay Shields LLC, Pacer Advisors Inc. and Rhumbline Advisers. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $63.27.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $1.25 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.
What is Enanta Pharmaceuticals' official website?
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
